Genentech is announcing positive results for its multiple sclerosis treatment. The South San Francisco company says its phase two study of fenebrutinib significantly reduced MS disease activity in the brain. The drug is now in phase three trials.
Genentech is announcing positive results for its multiple sclerosis treatment. The South San Francisco company says its phase two study of fenebrutinib significantly reduced MS disease activity in the brain. The drug is now in phase three trials.